Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Based on what is known about it's mechanism of action, bortezomib is presumed to make other
chemotherapy drugs work better. This study examines the use of bortezomib in combination with
an already effective chemotherapy regimen that is used to treat leukemias that have relapsed
or been refractory to treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University Thomas Jefferson University